27616886|t|The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate
27616886|a|This study was designed to improve the in vivo pharmacokinetics of long-circulating vincristine sulfate (VS)-loaded liposomes; three different long-circulating materials, chitosan, poly(ethylene glycol)-1,2-distearoyl sn-glycero-3-phosphatidylethanolamine (PEG-DSPE), and poly(ethylene glycol)-poly-lactide-co-glycolide (PEG-PLGA), were evaluated at the same coating molar ratio with the commercial product Marqibo (Â®) (vincristine sulfate liposome injection [VSLI]). VS-loaded liposomes were prepared by a pH gradient method and were then coated with chitosan, PEG-DSPE, or PEG-PLGA. Physicochemical properties, including the morphology, particle size, zeta potential, encapsulation efficiency (EE %), pH, drug loading, and in vitro release, were determined. Preservation stability and pharmacokinetic studies were performed to compare the membrane-coated liposomes with either commercially available liposomes or the VS solution. The sphere-like morphology of the vesicles was confirmed by transmission electron microscope. Increased particle size, especially for the chitosan formulation, was observed after the coating process. However, the EE % was ~99.0% with drug loading at 2.0 mg/mL, which did not change after the coating process. The coating of long-circulation materials, except for chitosan, resulted in negatively charged and stable vesicles at physiological pH. The near-zero zeta potential exhibited by the PEG-DSPE formulation leads to a long er circulation lifetime and improved absorption for VS, when compared with the PEG-PLGA formulation. Compared with the commercial product, PEG was responsible for a higher plasma VS concentration and a longer half-life. PEG-DSPE coating may be related to better absorption, based on the stability and a pharmacokinetic improvement in the blood circulation time.
27616886	27	53	long-circulating materials	T122	C0005479
27616886	61	77	pharmacokinetics	T039	C0031327
27616886	81	110	liposomal vincristine sulfate	T109,T121	C3497340
27616886	150	157	in vivo	T082	C1515655
27616886	158	174	pharmacokinetics	T039	C0031327
27616886	178	236	long-circulating vincristine sulfate (VS)-loaded liposomes	T109,T121	C0935690
27616886	216	218	VS	T109,T121	C0042680
27616886	254	280	long-circulating materials	T122	C0005479
27616886	282	290	chitosan	T109,T121	C0162969
27616886	292	366	poly(ethylene glycol)-1,2-distearoyl sn-glycero-3-phosphatidylethanolamine	T109	C0664515
27616886	368	376	PEG-DSPE	T109	C0664515
27616886	383	430	poly(ethylene glycol)-poly-lactide-co-glycolide	T109,T121	C3849743
27616886	432	440	PEG-PLGA	T109,T121	C3849743
27616886	470	477	coating	T080	C1522408
27616886	518	525	Marqibo	T109,T121	C1883536
27616886	531	576	vincristine sulfate liposome injection [VSLI]	T200	C4060177
27616886	579	598	VS-loaded liposomes	T109,T121	C0935690
27616886	618	636	pH gradient method	T059	C0022885
27616886	651	657	coated	T080	C1522408
27616886	663	671	chitosan	T109,T121	C0162969
27616886	673	681	PEG-DSPE	T109	C0664515
27616886	686	694	PEG-PLGA	T109,T121	C3849743
27616886	696	722	Physicochemical properties	UnknownType	C0683121
27616886	738	748	morphology	T080	C0332437
27616886	750	763	particle size	T081	C0030608
27616886	765	779	zeta potential	T067	C0597697
27616886	781	805	encapsulation efficiency	T081	C0013682
27616886	807	809	EE	T081	C0013682
27616886	814	816	pH	T081	C0020283
27616886	818	830	drug loading	UnknownType	C0678767
27616886	836	844	in vitro	T080	C1533691
27616886	845	852	release	T169	C1283071
27616886	871	883	Preservation	T059	C1514402
27616886	884	893	stability	T080	C0205360
27616886	898	921	pharmacokinetic studies	T062	C0201734
27616886	952	967	membrane-coated	T026	C1522987
27616886	968	977	liposomes	T109	C0023828
27616886	1013	1022	liposomes	T109	C0023828
27616886	1030	1032	VS	T109,T121	C0042680
27616886	1033	1041	solution	T122	C0525069
27616886	1047	1069	sphere-like morphology	T080	C0332437
27616886	1077	1085	vesicles	T026	C1622418
27616886	1103	1135	transmission electron microscope	T059	C0678118
27616886	1147	1160	particle size	T081	C0030608
27616886	1181	1189	chitosan	T109,T121	C0162969
27616886	1226	1233	coating	T080	C1522408
27616886	1234	1241	process	T067	C1522240
27616886	1256	1258	EE	T081	C0013682
27616886	1277	1289	drug loading	UnknownType	C0678767
27616886	1335	1342	coating	T080	C1522408
27616886	1343	1350	process	T067	C1522240
27616886	1367	1393	long-circulation materials	T122	C0005479
27616886	1406	1414	chitosan	T109,T121	C0162969
27616886	1428	1446	negatively charged	T196	C0003075
27616886	1451	1457	stable	T080	C0205360
27616886	1458	1466	vesicles	T026	C1622418
27616886	1470	1483	physiological	T169	C0205463
27616886	1484	1486	pH	T081	C0020283
27616886	1492	1516	near-zero zeta potential	T067	C0597697
27616886	1534	1542	PEG-DSPE	T109	C0664515
27616886	1566	1573	long er	T080	C0205166
27616886	1586	1594	lifetime	T079	C4071830
27616886	1608	1618	absorption	T070	C0000854
27616886	1623	1625	VS	T109,T121	C0042680
27616886	1650	1658	PEG-PLGA	T109,T121	C3849743
27616886	1710	1713	PEG	T109,T121,T122	C0032483
27616886	1743	1749	plasma	T031	C0032105
27616886	1750	1752	VS	T109,T121	C0042680
27616886	1753	1766	concentration	T081	C1446561
27616886	1773	1779	longer	T080	C0205166
27616886	1780	1789	half-life	T079	C0018517
27616886	1791	1799	PEG-DSPE	T109	C0664515
27616886	1800	1807	coating	T080	C1522408
27616886	1833	1843	absorption	T070	C0000854
27616886	1858	1867	stability	T080	C0205360
27616886	1874	1889	pharmacokinetic	T169	C0031328
27616886	1890	1901	improvement	T077	C2986411
27616886	1909	1931	blood circulation time	T060	C0919393